Generic Symlin Availability
Last updated on Jun 11, 2025.
Symlin is a brand name of pramlintide, approved by the FDA in the following formulation(s):
SYMLIN (pramlintide acetate - injectable;subcutaneous)
-
Manufacturer: ASTRAZENECA AB
Approval date: March 16, 2005
Strength(s): EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) (discontinued) -
Manufacturer: ASTRAZENECA AB
Approval date: September 25, 2007
Strength(s): EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) [RLD], EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) [RLD]
Is there a generic version of Symlin available?
No. There is currently no therapeutically equivalent version of Symlin available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Symlin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Symlin (pramlintide)
- Check interactions
- Compare alternatives
- Reviews (4)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: amylin analogs
- Breastfeeding
Patient resources
Other brands
Professional resources
Other formulations
Related treatment guides
Related/similar drugs
Lantus
Lantus is a long acting form of insulin used to treat type 1 or type 2 diabetes. Learn about side ...
Tresiba
Tresiba (insulin degludec) is used to treat diabetes mellitus. Includes Tresiba side effects ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Humalog
Humalog (insulin lispro) is used to treat type 1 (insulin-dependent) diabetes in adults. Includes ...
Levemir
Levemir (insulin detemir) is a long acting insulin used to treat diabetes in adults and children ...
Novolog
NovoLog is a fast-acting insulin used to treat diabetes to control blood sugar levels in adults and ...
Basaglar
Basaglar (insulin glargine) is a long-acting insulin that is used to improve blood sugar control in ...
Toujeo SoloStar
Toujeo (insulin glargine) is an injection used to treat type 1 or type 2 diabetes. Includes Toujeo ...
Admelog
Admelog (insulin lispro) is used to improve blood sugar control in patients with diabetes mellitus ...
Toujeo Max SoloStar
Toujeo Max SoloStar is used for diabetes, type 1, type 2 diabetes
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.